全文获取类型
收费全文 | 296653篇 |
免费 | 29136篇 |
国内免费 | 10803篇 |
专业分类
耳鼻咽喉 | 2117篇 |
儿科学 | 6264篇 |
妇产科学 | 4163篇 |
基础医学 | 55499篇 |
口腔科学 | 6328篇 |
临床医学 | 19414篇 |
内科学 | 48231篇 |
皮肤病学 | 4955篇 |
神经病学 | 25294篇 |
特种医学 | 6783篇 |
外国民族医学 | 80篇 |
外科学 | 23501篇 |
综合类 | 36563篇 |
现状与发展 | 42篇 |
预防医学 | 13277篇 |
眼科学 | 3451篇 |
药学 | 39521篇 |
55篇 | |
中国医学 | 10276篇 |
肿瘤学 | 30778篇 |
出版年
2023年 | 4318篇 |
2022年 | 5844篇 |
2021年 | 11144篇 |
2020年 | 10305篇 |
2019年 | 11619篇 |
2018年 | 11279篇 |
2017年 | 10947篇 |
2016年 | 10613篇 |
2015年 | 12422篇 |
2014年 | 17874篇 |
2013年 | 19672篇 |
2012年 | 17947篇 |
2011年 | 21344篇 |
2010年 | 17864篇 |
2009年 | 17490篇 |
2008年 | 16872篇 |
2007年 | 15345篇 |
2006年 | 13881篇 |
2005年 | 12190篇 |
2004年 | 10407篇 |
2003年 | 8979篇 |
2002年 | 6957篇 |
2001年 | 5988篇 |
2000年 | 5002篇 |
1999年 | 4332篇 |
1998年 | 3289篇 |
1997年 | 3182篇 |
1996年 | 2602篇 |
1995年 | 2684篇 |
1994年 | 2353篇 |
1993年 | 2054篇 |
1992年 | 1638篇 |
1991年 | 1473篇 |
1990年 | 1230篇 |
1989年 | 1026篇 |
1988年 | 930篇 |
1987年 | 810篇 |
1986年 | 895篇 |
1985年 | 1592篇 |
1984年 | 1684篇 |
1983年 | 1239篇 |
1982年 | 1322篇 |
1981年 | 1124篇 |
1980年 | 1016篇 |
1979年 | 810篇 |
1978年 | 597篇 |
1977年 | 484篇 |
1976年 | 500篇 |
1975年 | 406篇 |
1974年 | 297篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的 探讨不同时期慢性阻塞性肺疾病(COPD)患者血清诱饵受体3(DcR3)、凋亡抑制蛋白(Survivin)表达水平及临床意义。方法 选取2018年9月—2019年12月本院收治的92名COPD患者为研究对象,其中稳定型COPD 50例,急性加重期COPD 42例;同期本院健康体检者88例为对照组。测定各组研究对象血清DcR3、Survivin水平及肺功能指标。 与对照组[DcR3(106.54±48.35)pg/mL,Survivin(98.85±26.59)pg/mL]比较,稳定期组和急性加重期组血清DcR3[(395.23±123.85)pg/mL,(1 248.81±213.59)pg/mL]、Survivin [(267.54±84.69)pg/mL,(1 233.95±307.26)pg/mL]水平升高;与稳定期组比较,急性加重期组血清DcR3、Survivin水平升高。与对照组比较,稳定期组和急性加重期组FEV1%、FEV1 /FVC、DLCO%水平降低(P<0.001);与稳定期组比较,急性加重期组FEV1%、FEV1 /FVC、DLCO%水平降低(P<0.001)。随着低氧血症严重程度的增加,COPD患者血清DcR3、Survivin水平逐渐增加(P<0.001)。多因素logistics回归分析显示,高水平DcR3、Survivin、IL-12、hs-CRP为COPD病情的危险因素(P<0.001)。DcR3、Survivin与FEV、FEV1 /FVC呈负相关,与IL-12、TNF-α、hs-CRP呈正相关(P<0.001)。 COPD稳定期、急性加重期患者血清DcR3、Survivin表达水平升高,且DcR3、Survivin与COPD病情严重程度呈正相关。 相似文献
2.
《Saudi Pharmaceutical Journal》2022,30(6):669-678
BackgroundIschemia reperfusion (I/R) play an imperative role in the expansion of cardiovascular disease. Sinomenine (SM) has been exhibited to possess antioxidant, anticancer, anti-inflammatory, antiviral and anticarcinogenic properties. The aim of the study was scrutinized the cardioprotective effect of SM against I/R injury in rat.MethodsRat were randomly divided into normal control (NC), I/R control and I/R + SM (5, 10 and 20 mg/kg), respectively. Ventricular arrhythmias, body weight and heart weight were estimated. Antioxidant, inflammatory cytokines, inflammatory mediators and plasmin system indicator were accessed.ResultsPre-treated SM group rats exhibited the reduction in the duration and incidence of ventricular fibrillation, ventricular ectopic beat (VEB) and ventricular tachycardia along with suppression of arrhythmia score during the ischemia (30 and 120 min). SM treated rats significantly (P < 0.001) altered the level of antioxidant parameters. SM treatment significantly (P < 0.001) repressed the level of creatine kinase MB (CK-MB), creatine kinase (CK) and troponin I (Tnl). SM treated rats significantly (P < 0.001) repressed the tissue factor (TF), thromboxane B2 (TXB2), plasminogen activator inhibitor 1 (PAI-1) and plasma fibrinogen (Fbg) and inflammatory cytokines and inflammatory mediators.ConclusionOur result clearly indicated that SM plays anti-arrhythmia effect in I/R injury in the rats via alteration of oxidative stress and inflammatory reaction. 相似文献
3.
4.
5.
6.
7.
《Survey of ophthalmology》2023,68(5):940-956
Congenital aniridia is a panocular disorder that is typically characterized by iris hypoplasia and aniridia-associated keratopathy (AAK). AAK results in the progressive loss of corneal transparency and thereby loss of vision. Currently, there is no approved therapy to delay or prevent its progression, and clinical management is challenging because of phenotypic variability and high risk of complications after interventions; however, new insights into the molecular pathogenesis of AAK may help improve its management. Here, we review the current understanding about the pathogenesis and management of AAK. We highlight the biological mechanisms involved in AAK development with the aim to develop future treatment options, including surgical, pharmacological, cell therapies, and gene therapies. 相似文献
8.
9.
Osama Y Safdar Rana M Baghdadi Sereen A Alahmadi Bana E Fakieh Amaal M Algaydi 《World Journal of Clinical Pediatrics》2022,11(1):14-26
Whether the underlying mutations are homozygous, heterozygous, or co-inherited with other hemoglobinopathies, sickle cell disease is known to afflict the kidneys, leading to the clinical entity known as sickle cell nephropathy (SCN). Although common, SCN remains diagnostically elusive. Conventional studies performed in the context of renal disorders often fail to detect early stage SCN. This makes the quest for early diagnosis and treatment more challenging, and it increases the burden of chronic kidney disease-related morbidity among patients. Novel diagnostic tools have been employed to overcome this limitation. In this study, we discuss various biomarkers of SCN, including those employed in clinical practice and others recently identified in experimental settings, such as markers of vascular injury, endothelial dysfunction, tubulo-glomerular damage, and oxidative stress. These include kidney injury molecule-1, monocyte chemoattractant protein-1, N-acetyl-B-D-glucosaminidase, ceruloplasmin, orosomucoid, nephrin, and cation channels, among others. Furthermore, we explore the potential of novel biomarkers for refining diagnostic and therapeutic approaches and describe some obstacles that still need to be overcome. We highlight the importance of a collaborative approach to standardize the use of promising new biomarkers. Finally, we outline the limitations of conventional markers of renal damage as extensions of the pathogenic process occurring at the level of the organ and its functional subunits, with a discussion of the expected pattern of clinical and biochemical progression among patients with SCN. 相似文献
10.